Bausch & Lomb Corporation has announced it has acquired AcuFocus and its breakthrough intraocular lens (IOL) designed to offer extended depth of field for cataract patients.
Announcing the acquisition, Bausch & Lomb said the AcuFocus IC-8 Apthera IOL is the only small aperture non-toric extended depth of focus (EDOF) IOL for certain cataract patients who have as much as 1.5 dioptres of corneal astigmatism and wish to address presbyopia at the same time.
The IC-8 IOL is available in select markets across Europe, as well as in Australia, New Zealand, and Singapore. It is due to roll out in the United States this year.
Many patients receive a monofocal IOL at the time of cataract surgery, which may correct for distance vision, but not for presbyopia. Some available presbyopia-correcting IOLs have complex optics that split, shift, or stretch light to provide clear vision at more than one discrete focal point.
In contrast, the IC-8 Apthera IOL features proprietary small aperture technology that enables both distance vision correction and near vision correction to mitigate the effects of presbyopia, Bausch & Lomb said.
Describing cataracts as one of the largest contributors to global blindness, Bausch & Lomb CEO Joseph Papa said the company believes the “IC-8 Apthera EDOF IOL will bolster our surgical portfolio by enhancing our IOL offerings, which is a strategic area of focus for Bausch & Lomb”.
The financial terms of the transaction were not disclosed.